Bladder cancer is among the most expensive diseases in oncology in terms of treatment costs; each procedure requires days of hospitalisation and recurrence rates are high. Current unmet clinical needs can be addressed by optical methods due to the combination of non-invasive and real-time capture of unprecedented biomedical information. Recently, the project “Multi-modal, Endoscopic Biophotonic Imaging of Bladder Cancer for Point-of-Care Diagnosis (MIB)”, coordinated by DTU Fotonik, was submitted to H2020-PHC11 addressing exactly these issues. The MIB objective is to provide robust, easy-to-use, cost-effective optical methods with superior sensitivity and specificity to enable a step-change in point-of-care diagnostics of bladder cancer. The concept relies on combining optical methods (optical coherence tomography, multi-spectral opto-acoustic tomography, shifted excitation Raman difference spectroscopy, and multiphoton microscopy) providing structural, biochemical and functional information. The hypothesis is that such combination enables in situ diagnosis of bladder cancer with superior sensitivity and specificity due to unprecedented combined anatomic, biochemical and molecular tissue information.
With the support of Innovayt, the MIB project (grant no. 667933) was approved for funding and has received a grant of 6 million EUR over five years, starting Jan 2016, from the H2020 - PHC 11 topic.
Peter Andersen comments on Innovayt performance: “The collaboration with and support from Innovayt allowed me and the entire consortium to focus on carefully describing the technical parts and scientific excellence of the proposal. Also Innovayt facilitated the development and fine-tuning of the health-economic analysis thus supporting the business case of MIB. The entire collaboration has been seamless leaving an impression of Innovayt as a top professional partner.”
For more information click here